Transarterial chemoembolization plus camrelizumab is an effective and tolerable bridging therapy for patients with intermediate-stage hepatocellular carcinoma: A pilot study
Transarterial chemoembolization (TACE) has been reported to synergize with camrelizumab in the treatment of hepatocellular carcinoma (HCC). The present study aimed to explore the potential of TACE and camrelizumab as a bridging therapy prior to surgery for patients with HCC. For this purpose, 11 pat...
Gespeichert in:
| Veröffentlicht in: | Oncology letters 2023-11, Vol.26 (5), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 1 |
| container_title | Oncology letters |
| container_volume | 26 |
| creator | Huo, Haoran Wang, Xiaoying Xu, Shan Niu, Xiaotong Cheng, Limin Yuan, Zengjiang Huo, Shuang Fang, Pingping |
| description | Transarterial chemoembolization (TACE) has been reported to synergize with camrelizumab in the treatment of hepatocellular carcinoma (HCC). The present study aimed to explore the potential of TACE and camrelizumab as a bridging therapy prior to surgery for patients with HCC. For this purpose, 11 patients with HCC with intermediate stage disease [classified by China Liver Cancer (CNLC) staging] who received TACE combined with camrelizumab as a bridging therapy prior to surgery were enrolled in this study. The treatment response was evaluated at 2 weeks following TACE therapy and following camrelizumab treatment. The relapse-free survival (RFS) and overall survival (OS) of the patients were calculated. The objective response and disease control rates were 72.7 and 100.0% following TACE treatment, and were 100.0 and 100.0% following camrelizumab treatment, respectively. The [alpha]-fetoprotein levels gradually decreased following TACE, camrelizumab treatment and surgical resection (all P |
| doi_str_mv | 10.3892/o1.2023.14052 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A772562185</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A772562185</galeid><sourcerecordid>A772562185</sourcerecordid><originalsourceid>FETCH-LOGICAL-g675-503e2fa989a0cde458d43c2d7a07864435f8b7c0a405b8f490d1e572560337913</originalsourceid><addsrcrecordid>eNptkDFrHDEQhbdIIMZxmX4g9Z4l7WqlTXcY2zEY0lxvZqXRnoJWOiRdjP2f_B-jEBcpMlMM8_jmPZiu-8LZbtCzuE58J5gYdnxkUnzoLriaRc-ZGj91V6X8ZK3kxLWeLrq3Q8ZYMFfKHgOYI22JtiUF_4rVpwincC5gcMvUpPOGC_gCGIGcI1P9L2qLhZoCZVwCwZK9XX1coR6bcnoBlzKcmhfFWuDZ1yP42NI2sh4r9aXiSnCkhiRDIZwD5paXjY9pw2-wh5MPqUKpZ_vyufvoMBS6ep-X3eHu9nDzvX_8cf9ws3_s10nJXrKBhMNZz8iMpVFqOw5GWIVM6WkcB-n0ogzD9p5Fu3FmlpNUQk5sGNTMh8vu61_bFQM9-ehSzWg2X8zTXv3hBNeyUbv_UK0tbd6kSM43_Z-D33z4giE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Transarterial chemoembolization plus camrelizumab is an effective and tolerable bridging therapy for patients with intermediate-stage hepatocellular carcinoma: A pilot study</title><source>Spandidos Publications Journals</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Huo, Haoran ; Wang, Xiaoying ; Xu, Shan ; Niu, Xiaotong ; Cheng, Limin ; Yuan, Zengjiang ; Huo, Shuang ; Fang, Pingping</creator><creatorcontrib>Huo, Haoran ; Wang, Xiaoying ; Xu, Shan ; Niu, Xiaotong ; Cheng, Limin ; Yuan, Zengjiang ; Huo, Shuang ; Fang, Pingping</creatorcontrib><description>Transarterial chemoembolization (TACE) has been reported to synergize with camrelizumab in the treatment of hepatocellular carcinoma (HCC). The present study aimed to explore the potential of TACE and camrelizumab as a bridging therapy prior to surgery for patients with HCC. For this purpose, 11 patients with HCC with intermediate stage disease [classified by China Liver Cancer (CNLC) staging] who received TACE combined with camrelizumab as a bridging therapy prior to surgery were enrolled in this study. The treatment response was evaluated at 2 weeks following TACE therapy and following camrelizumab treatment. The relapse-free survival (RFS) and overall survival (OS) of the patients were calculated. The objective response and disease control rates were 72.7 and 100.0% following TACE treatment, and were 100.0 and 100.0% following camrelizumab treatment, respectively. The [alpha]-fetoprotein levels gradually decreased following TACE, camrelizumab treatment and surgical resection (all P<0.05). Of note, the CNLC stage decreased following treatment (P=0.007) and the downstaging success rate was 63.6%. In terms of survival profiles, the mean RFS (95% CI) was 14.1 (11.7-16.5) months and the 1-year RFS rate was 77.9+14.1%. Furthermore, the mean OS (95% CI) was 15.0 (13.2-16.8) months and the 1-year OS rate was 80.0+17.9%. Successful downstaging was associated with RFS (P=0.041), but not OS (P=0.221). With regard to safety, 6 (54.5%) patients experienced reactive cutaneous capillary endothelial proliferation, 5 (45.5%) patients reported pain and 4 (36.4%) patients had a fever. On the whole, the present study demonstrated that TACE plus camrelizumab may be an effective and safe strategy that has potential for use as a bridging strategy prior to surgery in patients with intermediate-stage HCC. Key words: hepatocellular carcinoma, transarterial chemoembolization, camrelizumab, bridging treatment, efficacy and safety</description><identifier>ISSN: 1792-1074</identifier><identifier>DOI: 10.3892/o1.2023.14052</identifier><language>eng</language><publisher>Spandidos Publications</publisher><subject>Drug therapy ; Glycoproteins ; Hepatoma ; Liver ; Liver diseases</subject><ispartof>Oncology letters, 2023-11, Vol.26 (5), p.1</ispartof><rights>COPYRIGHT 2023 Spandidos Publications</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Huo, Haoran</creatorcontrib><creatorcontrib>Wang, Xiaoying</creatorcontrib><creatorcontrib>Xu, Shan</creatorcontrib><creatorcontrib>Niu, Xiaotong</creatorcontrib><creatorcontrib>Cheng, Limin</creatorcontrib><creatorcontrib>Yuan, Zengjiang</creatorcontrib><creatorcontrib>Huo, Shuang</creatorcontrib><creatorcontrib>Fang, Pingping</creatorcontrib><title>Transarterial chemoembolization plus camrelizumab is an effective and tolerable bridging therapy for patients with intermediate-stage hepatocellular carcinoma: A pilot study</title><title>Oncology letters</title><description>Transarterial chemoembolization (TACE) has been reported to synergize with camrelizumab in the treatment of hepatocellular carcinoma (HCC). The present study aimed to explore the potential of TACE and camrelizumab as a bridging therapy prior to surgery for patients with HCC. For this purpose, 11 patients with HCC with intermediate stage disease [classified by China Liver Cancer (CNLC) staging] who received TACE combined with camrelizumab as a bridging therapy prior to surgery were enrolled in this study. The treatment response was evaluated at 2 weeks following TACE therapy and following camrelizumab treatment. The relapse-free survival (RFS) and overall survival (OS) of the patients were calculated. The objective response and disease control rates were 72.7 and 100.0% following TACE treatment, and were 100.0 and 100.0% following camrelizumab treatment, respectively. The [alpha]-fetoprotein levels gradually decreased following TACE, camrelizumab treatment and surgical resection (all P<0.05). Of note, the CNLC stage decreased following treatment (P=0.007) and the downstaging success rate was 63.6%. In terms of survival profiles, the mean RFS (95% CI) was 14.1 (11.7-16.5) months and the 1-year RFS rate was 77.9+14.1%. Furthermore, the mean OS (95% CI) was 15.0 (13.2-16.8) months and the 1-year OS rate was 80.0+17.9%. Successful downstaging was associated with RFS (P=0.041), but not OS (P=0.221). With regard to safety, 6 (54.5%) patients experienced reactive cutaneous capillary endothelial proliferation, 5 (45.5%) patients reported pain and 4 (36.4%) patients had a fever. On the whole, the present study demonstrated that TACE plus camrelizumab may be an effective and safe strategy that has potential for use as a bridging strategy prior to surgery in patients with intermediate-stage HCC. Key words: hepatocellular carcinoma, transarterial chemoembolization, camrelizumab, bridging treatment, efficacy and safety</description><subject>Drug therapy</subject><subject>Glycoproteins</subject><subject>Hepatoma</subject><subject>Liver</subject><subject>Liver diseases</subject><issn>1792-1074</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptkDFrHDEQhbdIIMZxmX4g9Z4l7WqlTXcY2zEY0lxvZqXRnoJWOiRdjP2f_B-jEBcpMlMM8_jmPZiu-8LZbtCzuE58J5gYdnxkUnzoLriaRc-ZGj91V6X8ZK3kxLWeLrq3Q8ZYMFfKHgOYI22JtiUF_4rVpwincC5gcMvUpPOGC_gCGIGcI1P9L2qLhZoCZVwCwZK9XX1coR6bcnoBlzKcmhfFWuDZ1yP42NI2sh4r9aXiSnCkhiRDIZwD5paXjY9pw2-wh5MPqUKpZ_vyufvoMBS6ep-X3eHu9nDzvX_8cf9ws3_s10nJXrKBhMNZz8iMpVFqOw5GWIVM6WkcB-n0ogzD9p5Fu3FmlpNUQk5sGNTMh8vu61_bFQM9-ehSzWg2X8zTXv3hBNeyUbv_UK0tbd6kSM43_Z-D33z4giE</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Huo, Haoran</creator><creator>Wang, Xiaoying</creator><creator>Xu, Shan</creator><creator>Niu, Xiaotong</creator><creator>Cheng, Limin</creator><creator>Yuan, Zengjiang</creator><creator>Huo, Shuang</creator><creator>Fang, Pingping</creator><general>Spandidos Publications</general><scope/></search><sort><creationdate>20231101</creationdate><title>Transarterial chemoembolization plus camrelizumab is an effective and tolerable bridging therapy for patients with intermediate-stage hepatocellular carcinoma: A pilot study</title><author>Huo, Haoran ; Wang, Xiaoying ; Xu, Shan ; Niu, Xiaotong ; Cheng, Limin ; Yuan, Zengjiang ; Huo, Shuang ; Fang, Pingping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g675-503e2fa989a0cde458d43c2d7a07864435f8b7c0a405b8f490d1e572560337913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Drug therapy</topic><topic>Glycoproteins</topic><topic>Hepatoma</topic><topic>Liver</topic><topic>Liver diseases</topic><toplevel>online_resources</toplevel><creatorcontrib>Huo, Haoran</creatorcontrib><creatorcontrib>Wang, Xiaoying</creatorcontrib><creatorcontrib>Xu, Shan</creatorcontrib><creatorcontrib>Niu, Xiaotong</creatorcontrib><creatorcontrib>Cheng, Limin</creatorcontrib><creatorcontrib>Yuan, Zengjiang</creatorcontrib><creatorcontrib>Huo, Shuang</creatorcontrib><creatorcontrib>Fang, Pingping</creatorcontrib><jtitle>Oncology letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huo, Haoran</au><au>Wang, Xiaoying</au><au>Xu, Shan</au><au>Niu, Xiaotong</au><au>Cheng, Limin</au><au>Yuan, Zengjiang</au><au>Huo, Shuang</au><au>Fang, Pingping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transarterial chemoembolization plus camrelizumab is an effective and tolerable bridging therapy for patients with intermediate-stage hepatocellular carcinoma: A pilot study</atitle><jtitle>Oncology letters</jtitle><date>2023-11-01</date><risdate>2023</risdate><volume>26</volume><issue>5</issue><spage>1</spage><pages>1-</pages><issn>1792-1074</issn><abstract>Transarterial chemoembolization (TACE) has been reported to synergize with camrelizumab in the treatment of hepatocellular carcinoma (HCC). The present study aimed to explore the potential of TACE and camrelizumab as a bridging therapy prior to surgery for patients with HCC. For this purpose, 11 patients with HCC with intermediate stage disease [classified by China Liver Cancer (CNLC) staging] who received TACE combined with camrelizumab as a bridging therapy prior to surgery were enrolled in this study. The treatment response was evaluated at 2 weeks following TACE therapy and following camrelizumab treatment. The relapse-free survival (RFS) and overall survival (OS) of the patients were calculated. The objective response and disease control rates were 72.7 and 100.0% following TACE treatment, and were 100.0 and 100.0% following camrelizumab treatment, respectively. The [alpha]-fetoprotein levels gradually decreased following TACE, camrelizumab treatment and surgical resection (all P<0.05). Of note, the CNLC stage decreased following treatment (P=0.007) and the downstaging success rate was 63.6%. In terms of survival profiles, the mean RFS (95% CI) was 14.1 (11.7-16.5) months and the 1-year RFS rate was 77.9+14.1%. Furthermore, the mean OS (95% CI) was 15.0 (13.2-16.8) months and the 1-year OS rate was 80.0+17.9%. Successful downstaging was associated with RFS (P=0.041), but not OS (P=0.221). With regard to safety, 6 (54.5%) patients experienced reactive cutaneous capillary endothelial proliferation, 5 (45.5%) patients reported pain and 4 (36.4%) patients had a fever. On the whole, the present study demonstrated that TACE plus camrelizumab may be an effective and safe strategy that has potential for use as a bridging strategy prior to surgery in patients with intermediate-stage HCC. Key words: hepatocellular carcinoma, transarterial chemoembolization, camrelizumab, bridging treatment, efficacy and safety</abstract><pub>Spandidos Publications</pub><doi>10.3892/o1.2023.14052</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1792-1074 |
| ispartof | Oncology letters, 2023-11, Vol.26 (5), p.1 |
| issn | 1792-1074 |
| language | eng |
| recordid | cdi_gale_infotracmisc_A772562185 |
| source | Spandidos Publications Journals; PubMed Central; EZB Electronic Journals Library |
| subjects | Drug therapy Glycoproteins Hepatoma Liver Liver diseases |
| title | Transarterial chemoembolization plus camrelizumab is an effective and tolerable bridging therapy for patients with intermediate-stage hepatocellular carcinoma: A pilot study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T07%3A25%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transarterial%20chemoembolization%20plus%20camrelizumab%20is%20an%20effective%20and%20tolerable%20bridging%20therapy%20for%20patients%20with%20intermediate-stage%20hepatocellular%20carcinoma:%20A%20pilot%20study&rft.jtitle=Oncology%20letters&rft.au=Huo,%20Haoran&rft.date=2023-11-01&rft.volume=26&rft.issue=5&rft.spage=1&rft.pages=1-&rft.issn=1792-1074&rft_id=info:doi/10.3892/o1.2023.14052&rft_dat=%3Cgale%3EA772562185%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A772562185&rfr_iscdi=true |